CHICAGO (Reuters)—U.S. scientists on Wednesday unveiled two new molecular editing tools designed to fix mutations that cause the majority of human genetic diseases, some of which have no known treatment. One technique, by David Liu of Harvard University and the Broad Institute of MIT and Harvard, offers a highly precise way to fix single-letter mistakes…
U.S. to Promote Use of Opioid Alternatives to Treat Addiction
(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…
Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme
BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…
Supplemental Application for Denosumab Goes to FDA
The FDA accepted for review a supplemental biologics license application for denosumab to treat patients with glucocorticoid-induced osteoporosis…
U.S. Judge to Review Trump Healthcare Payments Cut
SAN FRANCISCO (Reuters)—A U.S. judge is set to hear arguments on Monday about whether to block President Donald Trump’s decision to terminate controversial payments to health insurance companies under Obamacare. U.S. District Judge Vince Chhabria in San Francisco federal court has said he would quickly issue a ruling following the hearing. Several U.S. states sued…
GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy
LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…
Potential Biomarker for APS Identified
New research examines the role of factor Xa in the pathology of antiphospholipid syndrome (APS) and systemic lupus erythematosus-associated APS. Researchers found that FXa stimulation was mediated by protease-activated receptors and enhanced by IgG from FXa reactive antibody positive patients, which may make IgG FXa reactivity a novel biomarker for future research…
More Republican U.S. Senators Back Bipartisan Obamacare Deal
WASHINGTON (Reuters)—A bipartisan deal to stabilize Obamacare by restoring billions of dollars of federal subsidies to health insurers picked up Republican support in the Senate on Thursday despite President Donald Trump’s opposition but still faced an uphill battle. Republican Senator Lamar Alexander and Democratic Senator Patty Murray formally introduced legislation to shore up the insurance…
FDA Teams with Medical Companies in Puerto Rico to Tackle Shortages
(Reuters)—The head of the U.S. Food and Drug Administration said the agency was working with several pharmaceutical and medical device companies in Puerto Rico to prevent shortages of medical products in the U.S. as it joins a massive effort to help rebuild the island that was ravaged by Hurricane Maria.1 Drugmakers are working to get…
Obamacare Whiplash Leaves States, Insurers with Dueling Price Plans
NEW YORK (Reuters)—President Donald Trump’s reversals in the past week on maintaining Obamacare subsidies to insurers are sowing new confusion over what kind of health insurance will be available to consumers, and at what price, when enrollment for 2018 begins in two weeks. Trump said last week his administration would stop paying billions of dollars…
- « Previous Page
- 1
- …
- 170
- 171
- 172
- 173
- 174
- …
- 310
- Next Page »